Drug Trial Radar · NCT07072728
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
87
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Mar 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Psyence Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. Study details Participants in this study will be randomly allocated by chance (similar to flipping a coin) to one of three groups: a 25mg NPX-5 dose group, a 10 mg NPX-5 dose group or a 1mg NPX-5 dose group. Participants will be allocated a dose that will be administered during their psilocybin-assisted psychotherapy (PAP) dosing session. The PAP dosing session will run approximately 8 hours, with NPX-5 administered at Day 14 (dosing day). At Week 10, non-responders that continue to meet the study eligibility criteria may commence an additional PAP cycle (at 25 mg NPX-5). A maximum of 2 PAP cycles may be administered. Long term follow up will comprise of a study visit at 3 months post Week 10 (of the final cycle) to assess safety and tolerability of NPX-5. It is hoped that this research will develop important scientific knowledge that could contribute to the development of a potential new treatment for anxiety and depression after adjusting to an acutely stressful event such as a cancer diagnosis.
Conditions
- Adjustment Disorder
- Adjustment Disorder With Anxious Mood
- Cancer
- Cancer Cachexia
- Cancer of Endometrium
- Cancer of Kidney
- Cancer of Prostate
- Cancer of the Breast
- Cancer of Stomach
- Cancer Melanoma Skin
- Cancer Pancreas
Interventions
Psilocybin therapyDrug
Following a screening period, eligible participants will undergo one cycle of psilocybin-assisted psychotherapy (PAP). Non-responders at Week 10 who continue to meet eligibility criteria will be offered a second PAP cycle at the 25 mg NPX-5 dose. A maximum of two PAP cycles may be given. Long-term follow-up will include a visit at Month 3 following the final PAP cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anxiety SeverityTime frame: Comparison between treatment groups in the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score at Week 10 after a single PAP cycle.
- Number of participants with treatment-related adverse events as assessed by CTCAE V5.0Time frame: Assessment of Day 14 (dosing day) vital signs (pre-dose and prior to discharge).
- Safety and Tolerability of a Single Dose of NPX-5 using the Sheehan Suicide Tracking Scale (S-STS)Time frame: Assessment of suicidality using the Sheehan Suicide Tracking Scale (S-STS) at baseline, Day 13, Day 15, Weeks 4, 6, and 10, and 3 months post-final cycle.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Mind Medicine Australia Clinic
Abbotsford, Victoria, Australia · Recruiting
Neurocentrix
Melbourne, Victoria, Australia · Recruiting
Ramsay Northside Clinic
Melbourne, Victoria, Australia · Recruiting
Paratus Clinical Research Melbourne
Northcote, Victoria, Australia · Recruiting
Empax Centre
Leederville, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.